| Literature DB >> 27583400 |
Jessica Tilgner1, Klaus Thilo von Trotha1, Alexander Gombert1, Michael J Jacobs1,2, Maik Drechsler3,4, Yvonne Döring3,4, Oliver Soehnlein3,5,4, Jochen Grommes1,3.
Abstract
BACKGROUND: Treatment of acute lung injury (ALI) remains an unsolved problem in intensive care medicine. Recruitment of neutrophils into the lungs, regarded as a key mechanism in progression of ALI, depends on signaling between neutrophils and platelets. Consequently we explored the effect of platelet-targeted aspirin and tirofiban treatment in endotoxin induced acute lung injury.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27583400 PMCID: PMC5008681 DOI: 10.1371/journal.pone.0161218
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Aspirin reduces LPS-induced acute lung injury by interference with neutrophil recruitment.
Mice were challenged with LPS via inhalation and sacrificed 4 hours later. Mice were treated with aspirin (100μg/g bodyweight via intraperitoneal injection) 30 min before or 1 hour after LPS exposure as indicated. A: Quantification of alveolar (left), interstitial (middle), and intravascular neutrophils (right) in mice treated as indicated. B: protein concentration (left) and FITC-dextran clearance (right), in BAL fluids in mice treated as indicated. n = 6–8 for each bar. * indicates significant difference compared to LPS-treated animals.
Fig 2Aspirin, but not tirofiban prevents LPS-induced structural changes in the lung tissue.
A: Representative histological images of lungs from mice treated as indicated. B: Structural analyses of histological lung sections were made on based HE staining. * indicates significant difference compared to LPS-treated animals.
Fig 3Tirofiban displays no protective effect in LPS-induced acute lung injury.
Mice were challenged with LPS via inhalation and sacrificed 4 hours later. Mice were treated with tirofiban ((0.5μg/ g bodyweight via tail vein injection) 30 min before or 1 hour after LPS exposure as indicated. A: Quantification of alveolar (left), interstitial (middle), and intravascular neutrophils (right) in mice treated as indicated. B: protein concentration (left) and FITC-dextran clearance (right), in BAL fluids in mice treated as indicated. n = 6–8 for each bar. * indicates significant difference compared to LPS-treated animals.
Fig 4Expression of platelet-derived chemokines (CCL5 (RANTES) and CXCL4 (PF4)) and NET release.
Mice were challenged with LPS via inhalation and sacrificed 4 hours later. Mice were treated with tirofiban ((0.5μg/ g bodyweight via tail vein injection) 30 min before or 1 hour after LPS exposure as indicated or with aspirin (100μg/g bodyweight via intraperitoneal injection) 30 min before or 1 hour after LPS exposure as indicated. A: Plasma concentration of PF4 (CXCL4) after treatment as indicated. B: Plasma concentration of CCL5 after treatment as indicated. C and D: NET formation in the plasma (C) and supernatant of the lyzed lung (D). Values are presented as percentage increase of absorbance in comparison to the control group. n = 6–8 for each bar. * indicates significant difference compared to LPS-treated animals.